IT201700079551A1 - Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico - Google Patents

Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico

Info

Publication number
IT201700079551A1
IT201700079551A1 IT102017000079551A IT201700079551A IT201700079551A1 IT 201700079551 A1 IT201700079551 A1 IT 201700079551A1 IT 102017000079551 A IT102017000079551 A IT 102017000079551A IT 201700079551 A IT201700079551 A IT 201700079551A IT 201700079551 A1 IT201700079551 A1 IT 201700079551A1
Authority
IT
Italy
Prior art keywords
polychistic
calciomimetic
vasopressin
antagonists
kidney
Prior art date
Application number
IT102017000079551A
Other languages
English (en)
Inventor
Giovanna Valenti
Grazia Tamma
Mise Annarita Di
Marianna Ranieri
Original Assignee
Univ Degli Studi Di Bari Aldo Moro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Di Bari Aldo Moro filed Critical Univ Degli Studi Di Bari Aldo Moro
Priority to IT102017000079551A priority Critical patent/IT201700079551A1/it
Priority to US16/030,931 priority patent/US20190134054A1/en
Priority to EP18182982.1A priority patent/EP3427753A1/en
Publication of IT201700079551A1 publication Critical patent/IT201700079551A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT102017000079551A 2017-07-14 2017-07-14 Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico IT201700079551A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT102017000079551A IT201700079551A1 (it) 2017-07-14 2017-07-14 Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico
US16/030,931 US20190134054A1 (en) 2017-07-14 2018-07-10 Association of antagonists of the vasopressin receptor and calcimimetics, composition and use thereof for the treatment of polycystic kidney
EP18182982.1A EP3427753A1 (en) 2017-07-14 2018-07-11 Combination of antagonists of the vasopressin receptor and calciomimetics, composition and use thereof for the treatment of polycystic kidney

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000079551A IT201700079551A1 (it) 2017-07-14 2017-07-14 Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico

Publications (1)

Publication Number Publication Date
IT201700079551A1 true IT201700079551A1 (it) 2019-01-14

Family

ID=60382515

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000079551A IT201700079551A1 (it) 2017-07-14 2017-07-14 Associazione di antagonisti del recettore della vasopressina e calciomimetici, composizione e loro uso per il trattamento del rene policistico

Country Status (3)

Country Link
US (1) US20190134054A1 (it)
EP (1) EP3427753A1 (it)
IT (1) IT201700079551A1 (it)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008650A1 (en) * 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008650A1 (en) * 2006-07-10 2008-01-17 Indiana University Research And Technology Corporation Methods for treating cystic kidney diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. HIGASHIHARA ET AL: "Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience", CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 6, no. 10, 1 October 2011 (2011-10-01), pages 2499 - 2507, XP055074534, ISSN: 1555-9041, DOI: 10.2215/CJN.03530411 *
M. RANIERI ET AL: "Negative feedback from CaSR signaling to aquaporin-2 sensitizes vasopressin to extracellular Ca2+", JOURNAL OF CELL SCIENCE, vol. 128, no. 13, 14 May 2015 (2015-05-14), GB, pages 2350 - 2360, XP055454595, ISSN: 0021-9533, DOI: 10.1242/jcs.168096 *
NEAL X. CHEN ET AL: "Calcimimetics inhibit renal pathology in rodent nephronophthisis", KIDNEY INTERNATIONAL, vol. 80, no. 6, 1 September 2011 (2011-09-01), LONDON, GB, pages 612 - 619, XP055454577, ISSN: 0085-2538, DOI: 10.1038/ki.2011.139 *
V. E. TORRES: "Type II Calcimimetics and Polycystic Kidney Disease: Unanswered Questions", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY., vol. 20, no. 7, 1 July 2009 (2009-07-01), US, pages 1421 - 1425, XP055329528, ISSN: 1046-6673, DOI: 10.1681/ASN.2009050501 *

Also Published As

Publication number Publication date
US20190134054A1 (en) 2019-05-09
EP3427753A1 (en) 2019-01-16

Similar Documents

Publication Publication Date Title
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2017001987A1 (es) Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1
CL2016002382A1 (es) Derivados de quinoxalina útiles como moduladores de fgfr quinasa
ES2796903T8 (es) Procedimiento de uso de inmunoconjugados anti-CD79b
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112016015706A2 (pt) composto, uso do mesmo e composição farmacêutica
CL2014001858A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2017000271A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
BR112017006232A2 (pt) processos e intermediários na preparação de antagonistas de c5ar
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
ES2970224T3 (es) Tinostamustina para su uso en el tratamiento del sarcoma
CL2018000290A1 (es) Antagonistas del receptor de cgrp
CL2016002839A1 (es) Derivados de carboxamida
CL2018003417A1 (es) Nuevos compuestos.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
BR112017020374A2 (pt) compostos bicíclicos fundidos para o tratamento de doença
IT201600121617A1 (it) Composizione per il trattamento del reflusso gastroesofageo
EA201791937A1 (ru) Противовоспалительные полипептиды
DK3625221T3 (da) 3-Methyl-pyrrolidin-2,5-dion-derivater, der kan anvendes som CGRP-receptorantagonister
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
ITUA20161865A1 (it) Uso di lentinano per il trattamento e la prevenzione di endometriosi.
CL2018000941A1 (es) Regulación del uso de nitrógeno